KLDO - Kaleido Bio's KB109 shows positive effect in COVID-19 symptoms

Kaleido Biosciences (KLDO) reports positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19.KB109 demonstrated an overall favorable safety and tolerability profile with no treatment-related adverse events.Healthcare utilization, as measured by the total number of hospitalizations, emergency room visits, and urgent care visits was reduced by ~62% among patients with one or more comorbidity and by ~51% overall.For patients with one or more comorbidity, KB109 reduced median time to resolution of the 13 overall COVID-19 symptoms from 30 to 21 days (HR=1.422 [95% CI: 0.898, 2.250]; p=NS).Median time to resolution was significantly reduced from 31 to 21 days in patients age 45 years and older or with one or more comorbidity. The Company will host a conference call today at 8:30am ET to discuss the data.

For further details see:

Kaleido Bio's KB109 shows positive effect in COVID-19 symptoms